SEC Form 4 · accession 0001104659-18-004312
AGILE THERAPEUTICS INC · AGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alfred Altomari
Officer — Chief Executive Officer · Director
Period of report
Jan 24, 2018
Accepted (ET)
Jan 26, 2018 · 5:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001261249
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $3.46 | Jan 24, 2018 | A | 256,000 | A | — | Jan 23, 2028 | Common Stock | 256,000 | 256,000 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 24, 2018 | A | 35,314 | A | — | — | Common Stock | 35,314 | 51,981 | D |
Explanation of responses
- F1This option was granted on January 24, 2018. 25% of the shares subject to the stock option vest on January 24, 2019, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 24, 2022
- F2Each restricted stock unit represents a contingent right to receive one share of common stock.
- F3The restricted stock units were granted on January 24, 2018 and will be fully vested and delivered on January 24, 2019.